Immunotherapy in Small Cell Lung Cancer

Immunotherapy has shown promise in the treatment of small cell lung cancer (SCLC). SCLC is an aggressive form of lung cancer that is often treated with chemotherapy and radiation therapy.

However, these treatments can weaken the immune system, which can make it difficult to fight off the cancer. Immunotherapy works by boosting the immune systems ability to recognize and attack cancer cells.

There are currently several FDA approved immunotherapy drugs for the treatment of SCLC, including checkpoint inhibitors such as nivolumab and pembrolizumab. The drugs work by blocking the activity of a protein called PD-1, which is found on the surface of some immune cells.

PD-1 normally acts as a checkpoint to prevent the immune system from attacking healthy cells, but cancer cells can use PD-1 to evade immune surveillance. By blocking PD-1, checkpoint inhibitors it can enable the immune system to recognize the attacks of cancer cells.

Immunotherapy can also be combined with other treatments such as chemotherapy or radiation therapy to increase the effectiveness of treatment. In addition, researchers are exploring other immunotherapy approaches such as CAR-T cell therapy and cancer vaccines for the treatment of SCLC.

It is worth noting that immunotherapy is not effective for all patients and can cause side effects, including fatigue, rash, and autoimmune reactions. Therefore, it is important to discuss the potential benefits and risks of immunotherapy with your doctor.


Laura Zukerman

Owner and Founder At The Goddess Bibles

A Memoir By Laura Zukerman

Becoming Your Inner Goddess/God

Goddess/God On Fire ❤

My God, You Got This, Keep Going 🙂